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Background: In France, the proportion of MRSA has been over 25% since 2000. Prevention of hospital-acquired (HA)
MRSA spread is based on isolation precautions and antibiotic stewardship. At our institution, before 2000, the Infection
Disease and the Infection Control teams had failed to reduce HA-MRSA rates.
Objectives and methods: We implemented a multifaceted hospital-wide prevention program and measured the effects
on HA-MRSA colonization and bacteremia rates between 2000 and 2009. From 2000 to 2003, active screening and
decontamination of ICU patients, hospital wide alcohol based hand rubs (ABHR) use, control of specific classes of
antibiotics, compliance audits, and feed-backs to the care providers were successively implemented. The efficacy of the
program was assessed by HA-MRSA colonized and bacteremic patient rates per 1000 patient-days in patients hospitalized
for more than twenty-four hours.
Results: Compliance with the isolation practices increased between 2000 and 2009. Consumption of ABHR increased
from 6.8 L to 27.5 L per 1000 patient-days. The use of antibiotic Defined Daily Doses (DDD) per
1000 patient-days decreased by 31%. HA-MRSA colonization decreased by 84% from 1.09 to 0.17 per 1000
patient-days and HA-MRSA bacteremia by 93%, from 0.15 to 0.01 per 1000 patient-days (p<10−7 for each rate).
Conclusions: In an area highly endemic for MRSA, a multifaceted prevention program allows for sustainable reduction in
HA-MRSA bacteremia rates.
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Methicillin-resistant Staphylococcus aureus (MRSA) has
become a nosocomial pathogen worldwide [1-3]. The
European Antimicrobial Resistance Surveillance System
(EARSS) has documented that MRSA represents more
than 25% of the SA strains in France since 2000 [4].* Correspondence: bmisset@hpsj.fr
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reproduction in any medium, provided the orMRSA bacteremia is associated with an approximate
mortality rate of 50% [5]. Factors contributing to MRSA
bacteremia include the use of invasive devices, con-
centration of very sick patients, high work-load, micro-
organisms cross-transmission, and widespread use of
antibiotic therapy [6]. To improve this situation, current
recommendations are based on two approaches. The
first relies on barrier precautions, hand hygiene and envir-
onmental cleaning for MRSA patients. The second is
to decrease the antibiotic pressure by controlling anti-
biotic prescribing [6]. We implemented a program basedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antibiotic stewardship, associated with compliance assess-
ments and feed-back of the results to the care pro-
viders. We report the impact of this program on the
rates of HA-MRSA bacteremia from January 2000 to
December 2009.
Methods
Setting, case-mix and local background
The Saint-Joseph hospital is a private nonprofit hospital,
serving as a primary and tertiary care facility in Paris. It
has been running 450 adult care beds before 2006, and
540 beds since 2006, after merging with two hospitals
of the same area. This merge induced the implementa-
tion of three new activities: obstetrics and geriatrics
from 2006, and proctology from 2009. Thus, case-mix
changed, as assessed with the major diagnostic cate-
gories of the North-American derived French DRG
system prior activities were unchanged or increased, and
the new activities increased markedly (Figure 1). The
hospital includes two 10-bed Intensive Care Units (ICU).
The Infection Disease (ID) team, introduced in 1980,
has been giving advice to physicians in the wards for
patients with a positive microbiology result. Since 1993,
the Infection Control Unit implemented an alert system
for patients colonized with multi-resistant bacteria.
Despite these measures, the prevalence of MRSA
colonization had reached a high endemicity. By 1999,
0.94% of all admitted patients were colonized with
MRSA and MRSA acquisitions reached 1.06 per 1000
patient-days.
Prevention of cross-transmission
A program based on international recommendations [6]
was elaborated by the Infection Control Committee
(ICC). Preventive measures of cross-transmission were
updated each year since 1999. The clinician prescribes
microbiological samples according to the status of the
patient. Identification of MRSA is based on clinical
samples in the wards and on active screening in the
ICU [7], made upon admission and weekly, using BBL-
CHROMagar (BD Diagnostics, Heidelberg, Germany)
from 1999 and BD GeneOhm (MRSA) real-time PCR
assay (BD Diagnostics, San Diego, CA, USA) from 2003
[8]. Colonized patients are placed in contact isolation.
Training sessions for contact isolation have been carried
out twice a year in each unit since 2000. Barrier precau-
tions include the use of single rooms [9], gowns for con-
tact with the patient, and gloves for contact with
biological fluids. Room cleaning is performed twice a
day [10]. Disinfectant wipes are used for disinfection of
small items, including stethoscopes [11]. Alcoholic based
hand rubbing (ABHR) replaced hand washing in 2000.
Indications for ABHR are: [1] before and [2] aftercontact with the patient, [3] between two cares of the
same patient, [4] after contact with patient’s close envir-
onment, and [5] before any care events using aseptic
techniques [12]. ABHR dispensers are available in
patient’s room, on nurse’s trolley and for individual use.
Since 1999 in the ICU, decolonization of MRSA carriers
includes daily bathing with a povidone iodine antiseptic
soap [13], and three times daily nasal mupirocin during
five days [14].
Within 48 hours following the colonization, the Infec-
tion Control Unit assesses compliance with the isolation
measures. Since 2002, this unit audits twice a year
MRSA signaling, presence of ABHR, of gowns and of
disinfectant wipes in rooms.
Antibiotic stewardship
Once a year, the Pharmacy reports the evolution of
antibiotic Defined Daily Doses (DDD) per 1000 patient-
days to the ICC. Since 2002, in view of a shift of
prescriptions towards broad-spectrum antibiotics, the
pharmacy provides daily the list of the patients on anti-
biotics. The ID team has to visit all the patients on anti-
biotics, except surgical prophylaxis, for adjustments of
antibiotic prescribing.
MRSA rates
We included all patients admitted to hospital for at least
24 hours. Colonization was defined as isolation of MRSA
from any anatomical site, and bacteremia as isolation of
MRSA from a blood culture. Colonization and bacteremia
were classified as “hospital acquired” (HA) if the first
positive sample was taken after 48 hours of admission.
HA-MRSA colonized and bacteremic patients were
reported as incidence density rates per 1000 patient-days.
These rates were presented four times a year to the hos-
pital managers.
Ethical issues
The program underwent ethical review at the institu-
tional review board of the Saint-Joseph hospital and was
considered an epidemiological activity which did not
require patient consent to participate.
Statistical analysis
Changes in annual incidence rates of MRSA colonized
and/or bacteremic patients and antibiotic usage over the
study period were analyzed using the chi square test for
trends. The different interventions were unlikely to
affect data collection as sources and methods were the
same before and after the interventions, the outcome
variables were shown to the care providers but were
objective ones and considered reliable, all the patients
of the hospital were similarly assessed during the study
period. The link between annual ABHR use and
Figure 1 Evolution of the case-mix of the Saint-Joseph hospital over time. Legend: X axis: years. Y axis: number of patients admitted per
year. A: The case-mix is described with major diagnostic categories, derived from the diagnosed related group (DRG) system used in France. The
appearance of cases of pregnancy and neonates is due to the implementation of these activities in 2006. The major increase in digestive cases is
due to the implementation of a new activity of proctology in 2009. B: The increase in patient over 80 year old is due to the enlargement of the
geriatric unit in 2006.
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The number of admitted patients for more than 24 hours
was 171 366 during the 10 year period, representing 1
290 865 patient-days. The annual number of patients
increased from 12 403 in 2000 to 24 027 in 2009 due toan increase in bed capacity in 2006 and a reduction in
mean length of stay, from 9.13 days in 2000 to 6.38 days
in 2009. The annual number of surgical procedures
increased from 6 554 in 2000 to 9 647 in 2009 (Table 1).
Adherence to preventive measures
ABHR use increased from 6.8 L per 1000 patient-days in
2000 to 27.5 L in 2009 and was inversely proportional to
the incidence of HA-MRSA colonized patients (r2 = 0.94,
p < 10−3). Isolation practice determinants were assessed
Table 1 Description of the patient population admitted to the hospital
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Patients admitted for >24 h
Annual number of patient admissions 12 403 12 332 12 842 13 150 13 328 13 409 19 934 25 308 24 633 24 027
Annual number of patient-days 113 194 112 547 111 073 104 601 104 829 105 734 144 021 174 141 167 442 153 283
Average length of stays (days) 9.13 9.13 8.65 7.95 7.87 7.89 7.22 6.88 6.80 6.38
Mean age (years) 63.0 62.7 61.8 61.6 63.0 63.0 60.0 57.9 59.1 59.9
Annual number of surgical procedures 6 554 6 561 7 126 7 182 7 283 7 413 8 066 9 888 9 328 9 647
Annual number of patients admitted to the ICU 339 383 344 404 401 453 465 347 342 418
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nized with MRSA. Of these, 605 (70%) were hospitalized
in a single room. Compliance was close to 90% for the
presence of the sign on the patient’s door, and ABHR
and gowns in the room. The presence of disinfectant
wipes increased to 70% after 2 years of audits (Figure 2).
Antibiotic stewardship
From 2003 to 2009, the ID team carried out 25 328 formal
consults for 20 262 patients. The annual use of antibiotics
decreased by 31% from 812.4 to 561.8 DDD per 1000
patient-days between 2000 and 2009 (p<10−7). The use of
penicillins, cephalosporins, aminoglycosides, quinolones,
and glycopeptides decreased by 26%, 10%, 17%, 40% and
47% respectively (p<10−7 for each class) (Figure 3).
Incidence rates
We documented 1 380 MRSA colonized patients includ-
ing 557 HA cases (40.3%), and 122 MRSA blood stream
infections (BSI) including 56 HA-BSI cases (45.9%). An-
nual rates of HA-MRSA colonized patients decreased by
84%, from 1.09 to 0.17 per 1000 patient-days (p < 10−7).
Annual rates HA-MRSA bacteremic patients decreased
by 93% from 0.15 to 0.01 per 1000 patient-days (p < 10−7)
(Figure 4). The numbers of HA-MRSA bacteremic
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Figure 2 Surrogates of compliance with isolation precautions. Legend
during audits. *: Must be present in MRSA patient’s room. **: Disinfectant w
stethoscopes or portable Doppler probes.Discussion
Despite many attempts to combat MRSA spread, MRSA
is rapidly becoming endemic worldwide [3]. The long
term impact of an institutional program had not been
documented in the literature. In this study, we observed
a profound and sustained reduction in HA-MRSA
bacteremia by implementing a program based on cross-
transmission prevention measures and antibiotic stew-
ardship. This reduction occurred while the endemicity of
MRSA in France was among the highest in Europe [4].
MRSA bacteremia is a consequence of prior coloni-
zation [5]. Prevention of MRSA bacteremia must target
cross-infection and the use of antibiotics which select
resistant strains to methicillin [15]. Contact precautions
had an impact on the MRSA patient reservoir and the
rate of nosocomial MRSA bacteremia during an epi-
demic outbreak [16]. A reduction in MRSA bacteremia
was observed when isolation of ICU patients was based
on active screening [17]. Isolation in single rooms was
successful in the ICU [17] but not in peripheral wards
[9]. A program based on barrier precautions was able to
reduce the proportion of MRSA among S. aureus strains
in a French hospital network [18].
Several aspects of our program may have contributed
to the reduction of MRSA colonization and MRSA
related healthcare infections. This interventional pro-
gram was a long term strategy spanning and included007 2008 2009
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Figure 3 Use of quinolones, cephalosporins, aminoglycosides and glycopeptides over time. Legend: X axis: years. Y axis: defined daily dose
(DDD) per 1000 patient-days. Chi2 test for trends: p< 10−7 for each class of antibiotics.
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continuous professional education at all healthcare
worker levels. We observed an increase in the compli-
ance of the care providers to isolation measures. Annual
consumption of ABHR was correlated with the decrease
in HA-MRSA rates. We observed a decrease in both
MRSA colonization and MRSA BSI rates, consistent
with the fact that prior MRSA colonization precedes
infection. A progressive reduction of the MRSA reser-
voir size may have resulted in a reduction in the MRSA
colonization pressure [19]. To limit the emergence of
multi-resistant microorganisms [15], the ID team was
dedicated to give advice and reduce inappropriate use of
antibiotics. Antibiotic use decreased by 31% in 10 years
and the most important decrease was observed for quino-
lones and glycopeptides. In fact, quinolone use was asso-
ciated with MRSA isolation among hospitalized patients
[20] and patients previously exposed to quinolones are at
higher risk of acquiring MRSA [21]. By contrast to other
antibiotics, we attribute the decrease in glycopeptide use
to a consequence of the reduction in MRSA infections.
Our study has several limitations. First, we used a
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Figure 4 Hospital-acquired MRSA (HA-MRSA) per 1000 patient-days o
dotted line and bacteremic patients as solid line. Left Y axis: number of HA
of HA-MRSA bacteremic patients per 1000 patient-days. Chi2 test for trendsmay have been due to a change in MRSA epidemiology
outside the hospital. Yet, the EARSS network shows that
the rate of MRSA remained over 25% in France until
2007 [4]. We could not perform a time series analysis
because the intervention we implemented was a multifa-
ceted program which components started at different
times, depending on the evolution of guidelines and new
information from the medical literature. Therefore, we
could not determine a specific point in time when either
intervention occurred for the entire hospital nor assess a
sufficient number of observations between each inter-
vention to perform time series analysis [23].
Second, our hospital case-mix changed in 2006, when
90 acute care beds were added to the hospital. This
change in case-mix may have had an impact on MRSA
epidemiology. The increase in patients without much
co-morbidity (i.e. pregnant women) or with short hos-
pital stay (proctology procedures) may have reduced the
risk for MRSA cross-transmission while the increase in
elderly people may have increased this risk. Also, our
data shows an increasing number of surgical interven-
tions and patients admitted to the ICU, reflecting a sus-











ver time. Legend: X axis: years. Colonized patients are represented as
-MRSA colonized patients per 1000 patient-days. Right Y axis: number












Figure 5 Annual new cases of HA-MRSA colonized patients in ICU, medical wards and surgical wards. Legend: X axis: years. Y axis:
Crude number of new cases.
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sumption. Outside the ICU, we consider that the risk of
cross-transmission is higher in geriatric and vascular
patients, due to their relatively frequent chronic portage
of MRSA and/or open wounds. These populations have
increased during the study period. Additionally, the
decrease in MRSA bacteremia had begun largely before
2006. Therefore we estimate it unlikely that the reduction
in MRSA cross-transmission was substantially induced by
the change in case-mix we observed.
Third, active screening was not performed outside the
ICU. This was intentional [24] but may have led to missing
cases imported from the community and overestimated the
number of HA-MRSA. However, we observed a similar de-
crease in HA-MRSA rates in ICU patients. Fourth, the re-
sistance and virulence of MRSA strains may have changed
over the years. MRSA strains in the Paris area have become
more frequently sensitive to gentamicin since 1990, a fact
which was either due to a reduction in the use of gentami-
cin or to the introduction of various strains from outside
the hospital [25]. This resistance profile has not changed
substantially since 1995. An epidemic strain of Glycopep-
tide Intermediate SA (GISA) [26] was responsible for 9
cases of bacteremia during the year 2000. Recently, con-
siderable differences in the genetic diversity of MRSA
were documented between European countries [27], sug-
gesting that outbreaks play an important role in MRSA
epidemiology. Finally, the cost of our program was not
assessed. The reduction of MRSA bacteremia and anti-
biotic consumption we observed were the main benefits
for our patients at both the individual and collective
levels. The cost of MRSA nosocomial infections such as
pneumonia is high [28] and a continuous quality im-
provement (CQI) program was cost-effective [29] but the
respective roles of each aspect of a multifaceted program
remain to be assessed [30].
Conclusion
In an area endemic for MRSA, a program combining
several strategies aimed at reducing cross-transmissionand antibiotic selection pressure allowed for a profound
and sustained decrease in HA-MRSA bacteremia. The
multifaceted aspect of our program was considered
essential to its success. Future studies should address the
role of SA genetic diversity in MRSA endemics.
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